| | 209410-46-8 Basic information More.. |
| Product Name: | VX-745 | | Synonyms: | 6H-PYRIMIDO[1,6-B]PYRIDAZIN-6-ONE, 5-(2,6-DICHLOROPHENYL)-2-[(2,4-DIFLUOROPHENYL)THIO]- (9CI);6H-PYRIMIDO[1,6-B]PYRIDAZIN-6-ONE, 5-(2,6-DICHLOROPHENYL)-2-[(2,4-DIFLUOROPHENYL)THIO]-;5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one;5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyridazino[6,1-f]pyrimidin-6-one;5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenylsulfanyl)-6H-pyriMido[3,4-b]pyridazin-6-one;VX-745(VX 745);5-(2,6-Dichloro-phenyl)-2-(2,4-difluoro-phenylsulfanyl)-1,7,8a-triaza-naphthalen-6-one;5-(2,6-Dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyridazino[6,1-f]pyrimidin-6-one VX-745 | | CAS: | 209410-46-8 | | MF: | C19H9Cl2F2N3OS | | MW: | 436.26 | | EINECS: | | | Mol File: | 209410-46-8.mol |  |
Use
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of
Werner syndrome.
- Neflamapimod
-
- US $43.00-128.00 / mg
- 2025-08-29
- CAS:209410-46-8
- Min. Order:
- Purity: 99.02%
- Supply Ability: 10g
|
|
209410-46-8
Recommend Suppliers |
|